Altimmune Inc (ALT)

$4.56 -0.01 (-0.22%)
Market Cap 510.01M
Revenue (ttm) 20,000.00
Net Income (ttm) -95.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475,300.00%
Debt to Equity Ratio 0.08
Volume 2,050,957
Avg Vol 5,212,714
Day's Range N/A - N/A
Shares Out 112.83M
Stochastic %K 54%
Beta 0.09
Analysts Strong Sell
Price Target $17.78

Company Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology
Sector: Healthcare
Phone: 240 654 1450
Address:
910 Clopper Road, Suite 201S, Gaithersburg, United States
six_eight
six_eight Feb. 25 at 9:36 PM
$ALT are they reporting tomorrow?
0 · Reply
TradeSun
TradeSun Feb. 25 at 9:36 PM
$ALT $AUTL Nice double beat for NVDA. Good for tomorrows market!👍 A domani!☀️
0 · Reply
MySfinktrReeks
MySfinktrReeks Feb. 25 at 9:35 PM
$ALT this company is an embarrassment.
0 · Reply
BioRich
BioRich Feb. 25 at 9:35 PM
$ALT @Turribull Oh Billy, of you're going to play hypotheticals, why don't you go ahead and adjust those PTs for dilution. Many of the PTs were made when fully diluted shares were 77M or less. We are at ~149M now. So with your simple math and my simple logic, consensus PT for $ALT is ~$10 (w/o GS). Doesn't quite have the same energy. Y'all can keep coming up with hope, and I'll keep sharing reality.
0 · Reply
GreenEnergy2022
GreenEnergy2022 Feb. 25 at 9:30 PM
$ALT An earnings report "quiet period" (also known as a black-out period) is a self-imposed or regulatory-mandated timeframe, typically lasting around 30 days (or 4 weeks) before a public company releases its quarterly earnings results, during which management restricts communication with investors, analysts, and the media to avoid disclosing material non-public information
0 · Reply
TradeSun
TradeSun Feb. 25 at 9:25 PM
$ALT @Turribull 19.5M at the 🛎️ for NVDA!! The future of Altimmune😎😉
1 · Reply
Definvest
Definvest Feb. 25 at 9:17 PM
$ALT The ‘Durso is a plant’ story makes a comeback. But on a serious note, how would we know this is not the case actually? It’s been 2 months since I’m waiting for him to speak about the path forward and it’s crickets so far.
1 · Reply
BirdnDiz
BirdnDiz Feb. 25 at 9:12 PM
$ALT Genuine question. What importance is an earnings report for a company that doesn’t sell anything? Regardless,still
3 · Reply
StockMktGuru
StockMktGuru Feb. 25 at 9:05 PM
$ALT Secret CEO who controls our CEO 😆 🤣 😂 😹 You got to serve somebody if not retail investors some secret investors. As expected no news, no earnings release and complete zipper on this managements lips. Trojan horse sent to acquire the Co from within. So much for clarity and ability to identify the roadmap and discuss it in details "once" Durso takes over on 1st Jan. Soon it will be March does this sound like a CEO who is in control of himself or is someone else pulling strings on this dummy?
0 · Reply
LeeroyJenkins2
LeeroyJenkins2 Feb. 25 at 9:05 PM
$ALT I guess I’ll be a fan of the early Thursday morning PR
0 · Reply
Latest News on ALT
Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 22 days ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

AMGN GPCR LLY NVO PFE VKTX

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

Jan 29, 2026, 5:54 PM EST - 26 days ago

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

Altimmune (ALT) Shares Slide On $75 Million Stock Offering

Jan 28, 2026, 4:13 PM EST - 4 weeks ago

Altimmune (ALT) Shares Slide On $75 Million Stock Offering

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

Jan 27, 2026, 9:25 PM EST - 4 weeks ago

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Jan 5, 2026, 7:30 AM EST - 7 weeks ago

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen

Dec 23, 2025, 7:42 PM EST - 2 months ago

Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen

Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks

Dec 19, 2025, 12:57 PM EST - 2 months ago

Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks

Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript

Dec 19, 2025, 11:37 AM EST - 2 months ago

Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Dec 19, 2025, 6:42 AM EST - 2 months ago

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Dec 19, 2025, 6:30 AM EST - 2 months ago

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Altimmune Announces CEO Transition and Succession Plan

Dec 1, 2025, 7:30 AM EST - 3 months ago

Altimmune Announces CEO Transition and Succession Plan

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 7:30 AM EST - 3 months ago

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 20, 2025, 3:03 PM EST - 3 months ago

Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Altimmune: Probing Pemvi's MASH Data

Nov 14, 2025, 3:23 AM EST - 3 months ago

Altimmune: Probing Pemvi's MASH Data

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Nov 11, 2025, 8:51 AM EST - 3 months ago

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Nov 7, 2025, 8:05 AM EST - 3 months ago

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 2:26 PM EST - 3 months ago

Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Nov 6, 2025, 7:00 AM EST - 3 months ago

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Altimmune to Participate in Two Upcoming Investor Conferences

Nov 5, 2025, 7:30 AM EST - 4 months ago

Altimmune to Participate in Two Upcoming Investor Conferences

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Nov 3, 2025, 7:30 AM EST - 4 months ago

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Oct 30, 2025, 7:30 AM EDT - 4 months ago

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

Oct 20, 2025, 7:30 AM EDT - 4 months ago

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

Oct 6, 2025, 10:09 AM EDT - 5 months ago

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Oct 5, 2025, 11:40 PM EDT - 5 months ago

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Oct 3, 2025, 9:50 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 30, 2025, 10:20 AM EDT - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

Sep 29, 2025, 7:30 AM EDT - 5 months ago

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 21, 2025, 8:39 AM EDT - 5 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

Sep 19, 2025, 10:27 AM EDT - 5 months ago

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

SLQT

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Sep 18, 2025, 8:45 AM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Sep 15, 2025, 7:30 AM EDT - 5 months ago

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 11:20 AM EDT - 6 months ago

Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)

Aug 27, 2025, 5:17 PM EDT - 6 months ago

Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)

Altimmune to Participate in Upcoming Investor Conferences

Aug 26, 2025, 7:30 AM EDT - 6 months ago

Altimmune to Participate in Upcoming Investor Conferences

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Aug 19, 2025, 7:30 AM EDT - 6 months ago

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

Aug 15, 2025, 12:06 PM EDT - 6 months ago

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

six_eight
six_eight Feb. 25 at 9:36 PM
$ALT are they reporting tomorrow?
0 · Reply
TradeSun
TradeSun Feb. 25 at 9:36 PM
$ALT $AUTL Nice double beat for NVDA. Good for tomorrows market!👍 A domani!☀️
0 · Reply
MySfinktrReeks
MySfinktrReeks Feb. 25 at 9:35 PM
$ALT this company is an embarrassment.
0 · Reply
BioRich
BioRich Feb. 25 at 9:35 PM
$ALT @Turribull Oh Billy, of you're going to play hypotheticals, why don't you go ahead and adjust those PTs for dilution. Many of the PTs were made when fully diluted shares were 77M or less. We are at ~149M now. So with your simple math and my simple logic, consensus PT for $ALT is ~$10 (w/o GS). Doesn't quite have the same energy. Y'all can keep coming up with hope, and I'll keep sharing reality.
0 · Reply
GreenEnergy2022
GreenEnergy2022 Feb. 25 at 9:30 PM
$ALT An earnings report "quiet period" (also known as a black-out period) is a self-imposed or regulatory-mandated timeframe, typically lasting around 30 days (or 4 weeks) before a public company releases its quarterly earnings results, during which management restricts communication with investors, analysts, and the media to avoid disclosing material non-public information
0 · Reply
TradeSun
TradeSun Feb. 25 at 9:25 PM
$ALT @Turribull 19.5M at the 🛎️ for NVDA!! The future of Altimmune😎😉
1 · Reply
Definvest
Definvest Feb. 25 at 9:17 PM
$ALT The ‘Durso is a plant’ story makes a comeback. But on a serious note, how would we know this is not the case actually? It’s been 2 months since I’m waiting for him to speak about the path forward and it’s crickets so far.
1 · Reply
BirdnDiz
BirdnDiz Feb. 25 at 9:12 PM
$ALT Genuine question. What importance is an earnings report for a company that doesn’t sell anything? Regardless,still
3 · Reply
StockMktGuru
StockMktGuru Feb. 25 at 9:05 PM
$ALT Secret CEO who controls our CEO 😆 🤣 😂 😹 You got to serve somebody if not retail investors some secret investors. As expected no news, no earnings release and complete zipper on this managements lips. Trojan horse sent to acquire the Co from within. So much for clarity and ability to identify the roadmap and discuss it in details "once" Durso takes over on 1st Jan. Soon it will be March does this sound like a CEO who is in control of himself or is someone else pulling strings on this dummy?
0 · Reply
LeeroyJenkins2
LeeroyJenkins2 Feb. 25 at 9:05 PM
$ALT I guess I’ll be a fan of the early Thursday morning PR
0 · Reply
Hatrak1
Hatrak1 Feb. 25 at 9:01 PM
$ALT
0 · Reply
maximzzx
maximzzx Feb. 25 at 9:00 PM
$ALT at least we had 2 green days...
1 · Reply
Amnesiac
Amnesiac Feb. 25 at 9:00 PM
$ALT
0 · Reply
Benedictus
Benedictus Feb. 25 at 8:55 PM
$ALT
0 · Reply
BioRich
BioRich Feb. 25 at 8:52 PM
$ALT For those shifting to AUD, don't forget this was a distraction carrot wave by $ALT after the decided to not pursue Obesity/Weight Loss as an indication (and weren't mature enough to admit it yet). Also, don't forget $ALT Vice President of Clinical Development left IMMEDIATELY following this charade. Congrats to you Dr. Browne for maintaining integrity in a world where it often lacks. Praying for a full recovery from your health scare following your departure from $ALT and best of luck in your new endeavors. Cheers. #AUDisAJoke #AUDdistraction #ALDdistraction #ObesityDiscontinuation #ScrapInSilence.
0 · Reply
denzo2
denzo2 Feb. 25 at 8:50 PM
$ALT Are the secret investor, the secret ER date, the secret Pemvi oral data and the secret other stuff all related??🤔
4 · Reply
GreenEnergy2022
GreenEnergy2022 Feb. 25 at 8:50 PM
$ALT ALT is in a "wait and see -phase", low volume
0 · Reply
roadto2M
roadto2M Feb. 25 at 8:44 PM
$ALT
0 · Reply
BioRich
BioRich Feb. 25 at 8:42 PM
$ALT Even after $ALT purposely designed their MASH trial to "lower the placebo response rate", they still FAILED miserably and convincingly. For those holding onto hope, never forget this image. You hate it, but BP loves it because it saved them billions. Chew on that... Follow/Subscribe for more thoughts and perspective. Would love to hear yours as well. That's how we learn. Cheers! $XBI
1 · Reply
Amnesiac
Amnesiac Feb. 25 at 8:39 PM
$ALT Gaaaaaaaaaaaaaaaarg!!!
1 · Reply
Hatrak1
Hatrak1 Feb. 25 at 8:39 PM
$ALT We should get a PR today right ? Since most platforms show the 26th for ER ?
1 · Reply
BigCheeze2014
BigCheeze2014 Feb. 25 at 8:38 PM
$ALT SUCKS!!!
0 · Reply